<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37743418</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-3635</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Signal transduction and targeted therapy</Title><ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation></Journal><ArticleTitle>Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors.</ArticleTitle><Pagination><StartPage>366</StartPage><MedlinePgn>366</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">366</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-023-01603-4</ELocationID><Abstract><AbstractText>With the continuous in-depth study of the interaction mechanism between viruses and hosts, the virus has become a promising tool in cancer treatment. In fact, many oncolytic viruses with selectivity and effectiveness have been used in cancer therapy. Human enterovirus is one of the most convenient sources to generate oncolytic viruses, however, the high seroprevalence of some enteroviruses limits its application which urges to exploit more oncolytic enteroviruses. In this study, coxsackievirus B5/Faulkner (CV-B5/F) was screened for its potential oncolytic effect against non-small cell lung cancers (NSCLCs) through inducing apoptosis and autophagy. For refractory NSCLCs, DNA-dependent protein kinase (DNA-PK) or ataxia telangiectasia mutated protein (ATM) inhibitors can synergize with CV-B5/F to promote refractory cell death. Here, we showed that viral infection triggered endoplasmic reticulum (ER) stress-related pro-apoptosis and autophagy signals, whereas repair for double-stranded DNA breaks (DSBs) contributed to cell survival which can be antagonized by inhibitor-induced cell death, manifesting exacerbated DSBs, apoptosis, and autophagy. Mechanistically, PERK pathway was activated by the combination of CV-B5/F and inhibitor, and the irreversible ER stress-induced exacerbated cell death. Furthermore, the degradation of activated STING by ERphagy promoted viral replication. Meanwhile, no treatment-related deaths due to CV-B5/F and/or inhibitors occurred. Conclusively, our study identifies an oncolytic CV-B5/F and the synergistic effects of inhibitors of DNA-PK or ATM, which is a potential therapy for NSCLCs.</AbstractText><CopyrightInformation>© 2023. West China Hospital, Sichuan University.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cui</LastName><ForeName>Bopei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Song</LastName><ForeName>Lifang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kelei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Minhai Biotechnology Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mingchen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Minhai Biotechnology Co., Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qiushuang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Chaoying</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Xiaotian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Fangyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taibang Biologic Group, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiuyue</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Taibang Biologic Group, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changchun Institute of Biological Products Co., Ltd, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ziyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Biological Products Co., Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xujia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changchun Institute of Biological Products Co., Ltd, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China. maoqunying@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-2598-4355</Identifier><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan, China. yangxiaoming@sinopharm.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>China National Biotec Group Company Limited, Beijing, China. yangxiaoming@sinopharm.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China. lzhenglun@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Signal Transduct Target Ther</MedlineTA><NlmUniqueID>101676423</NlmUniqueID><ISSNLinking>2059-3635</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>24</Day><Hour>23</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37743418</ArticleId><ArticleId IdType="pmc">PMC10518312</ArticleId><ArticleId IdType="doi">10.1038/s41392-023-01603-4</ArticleId><ArticleId IdType="pii">10.1038/s41392-023-01603-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400:563–591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9395583</ArticleId><ArticleId IdType="pubmed">35988567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, et al. The landscape of cell and gene therapies for solid tumors. Cancer Cell. 2021;39:7–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33434513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 2015;14:642–662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097180</ArticleId><ArticleId IdType="pubmed">26323545</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan PA, Beaulieu C, Patel RB, Lowe DK. Talimogene Laherparepvec: an oncolytic virus therapy for melanoma. Ann. Pharmacother. 2017;51:675–681.</Citation><ArticleIdList><ArticleId IdType="pubmed">28351167</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Su C, Qin L. Current landscape and perspective of oncolytic viruses and their combination therapies. Transl. Oncol. 2022;25:101530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9472052</ArticleId><ArticleId IdType="pubmed">36095879</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayawardena N, Poirier JT, Burga LN, Bostina M. Virus-receptor interactions and virus neutralization: insights for oncolytic virus development. Oncolytic Virother. 2020;9:1–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7064293</ArticleId><ArticleId IdType="pubmed">32185149</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkeley RA, et al. Antibody-neutralized reovirus is effective in oncolytic virotherapy. Cancer Immunol. Res. 2018;6:1161–1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">30209061</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren DR, et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin. Cancer Res. 2004;10:53–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734451</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72:2609–2621.</Citation><ArticleIdList><ArticleId IdType="pubmed">22461509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L, Liu Z. Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer. Cancer Med. 2020;9:5210–5220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7367620</ArticleId><ArticleId IdType="pubmed">32459400</ArticleId></ArticleIdList></Reference><Reference><Citation>Doniņa S, et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25:421–426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4560272</ArticleId><ArticleId IdType="pubmed">26193376</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials. gov [2022-09-15]. https://clinicaltrials.gov/ct2/show/NCT01227551(2022).</Citation></Reference><Reference><Citation>Stewart G, Chantry A, Lawson M. The use of oncolytic viruses in the treatment of multiple myeloma. Cancers. 2021;13:5687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8616105</ArticleId><ArticleId IdType="pubmed">34830842</ArticleId></ArticleIdList></Reference><Reference><Citation>Davila-Calderon J, et al. IRES-targeting small molecule inhibits enterovirus 71 replication via allosteric stabilization of a ternary complex. Nat. Commun. 2020;11:4775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7508794</ArticleId><ArticleId IdType="pubmed">32963221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu R, et al. Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. Emerg. Microbes Infect. 2018;7:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837151</ArticleId><ArticleId IdType="pubmed">29323107</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, et al. A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1. Oncotarget. 2016;7:48443–48455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5217030</ArticleId><ArticleId IdType="pubmed">27374176</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci. Transl. Med. 2017;9:eaam7996.</Citation><ArticleIdList><ArticleId IdType="pubmed">28835517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y, et al. Selective antagonism of Bcl-xL potentiates M1 oncolysis by enhancing mitochondrial apoptosis. Hum. Gene. Ther. 2018;29:950–961.</Citation><ArticleIdList><ArticleId IdType="pubmed">28750564</ArticleId></ArticleIdList></Reference><Reference><Citation>Smithee S, Tracy S, Chapman NM. Reversion to wildtype of a mutated and nonfunctional coxsackievirus B3CRE(2C) Virus Res. 2016;220:136–149.</Citation><ArticleIdList><ArticleId IdType="pubmed">27130630</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes R, Guerra-Sá R, Arruda E. Coxsackievirus B5 induced apoptosis of HeLa cells: effects on p53 and SUMO. Virology. 2010;396:256–263.</Citation><ArticleIdList><ArticleId IdType="pubmed">19906394</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, et al. Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant lung adenocarcinoma. Mol. Ther. Oncolytics. 2019;14:266–278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6709373</ArticleId><ArticleId IdType="pubmed">31463367</ArticleId></ArticleIdList></Reference><Reference><Citation>Morillon Y, et al. The use of a humanized NSG-β2m-/- model for investigation of immune and anti-tumor effects mediated by the bifunctional immunotherapeutic Bintrafusp Alfa. Front. Oncol. 2020;10:549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186351</ArticleId><ArticleId IdType="pubmed">32373533</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers SE, et al. Prevalent human coxsackie B-5 virus infects porcine islet cells primarily using the coxsackie-adenovirus receptor. Xenotransplantation. 2004;11:536–546.</Citation><ArticleIdList><ArticleId IdType="pubmed">15479464</ArticleId></ArticleIdList></Reference><Reference><Citation>Krysko DV, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer. 2012;12:860–875.</Citation><ArticleIdList><ArticleId IdType="pubmed">23151605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547:99–103.</Citation><ArticleIdList><ArticleId IdType="pubmed">28459430</ArticleId></ArticleIdList></Reference><Reference><Citation>Machida K, et al. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J. Virol. 2006;80:7199–7207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489016</ArticleId><ArticleId IdType="pubmed">16809325</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez I, et al. Induction of DNA double-strand breaks and cellular senescence by human respiratory syncytial virus. Virulence. 2016;7:427–442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871660</ArticleId><ArticleId IdType="pubmed">26809688</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun T, Li X, Shen P. Modeling amplified p53 responses under DNA-PK inhibition in DNA damage response. Oncotarget. 2017;8:17105–17114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5370026</ArticleId><ArticleId IdType="pubmed">28177883</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano MA, et al. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene. 2013;32:2452–2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651755</ArticleId><ArticleId IdType="pubmed">22797063</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Zhang X, Wang M, Lin Y, Zhou S. Stigmasterol simultaneously induces apoptosis and protective autophagy by inhibiting Akt/mTOR pathway in gastric cancer cells. Front. Oncol. 2021;11:629008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7940753</ArticleId><ArticleId IdType="pubmed">33708631</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder PK, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004;10:594–601.</Citation><ArticleIdList><ArticleId IdType="pubmed">15156201</ArticleId></ArticleIdList></Reference><Reference><Citation>He B. Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ. 2006;13:393–403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16397582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjitha HB, et al. Foot-and-mouth disease virus induces PERK-mediated autophagy to suppress the antiviral interferon response. J. Cell Sci. 2020;134:jcs240622.</Citation><ArticleIdList><ArticleId IdType="pubmed">32482793</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 2012;13:89–102.</Citation><ArticleIdList><ArticleId IdType="pubmed">22251901</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon H, et al. IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 2013;32:2751–2763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3801437</ArticleId><ArticleId IdType="pubmed">24065129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q, et al. Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease. Proc. Natl Acad. Sci. USA. 2018;115:E6310–E6318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142274</ArticleId><ArticleId IdType="pubmed">29915078</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. STING1 is essential for an RNA-virus triggered autophagy. Autophagy. 2022;18:816–828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9037512</ArticleId><ArticleId IdType="pubmed">34338134</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RS, et al. DDX41 is required for cGAS-STING activation against DNA virus infection. Cell Rep. 2022;39:110856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9205463</ArticleId><ArticleId IdType="pubmed">35613581</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, et al. RIG-I-mediated STING upregulation restricts herpes simplex virus 1 infection. J. Virol. 2016;90:9406–9419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5044816</ArticleId><ArticleId IdType="pubmed">27512060</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai J, Liu F. Nuclear cGAS: sequestration and beyond. Protein Cell. 2022;13:90–101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8783940</ArticleId><ArticleId IdType="pubmed">34374004</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S, et al. Nuclear cGAS functions non-canonically to enhance antiviral immunity via recruiting methyltransferase Prmt5. Cell Rep. 2020;33:108490.</Citation><ArticleIdList><ArticleId IdType="pubmed">33296647</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, et al. Atomic structures of coxsackievirus B5 provide key information on viral evolution and survival. J. Virol. 2022;96:e0010522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9093117</ArticleId><ArticleId IdType="pubmed">35442060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn J, et al. Primary neurons become less susceptible to coxsackievirus B5 following maturation: the correlation with the decreased level of CAR expression on cell surface. J. Med. Virol. 2008;80:434–440.</Citation><ArticleIdList><ArticleId IdType="pubmed">18205224</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers. J. Mol. Histol. 2006;37:153–160.</Citation><ArticleIdList><ArticleId IdType="pubmed">17031523</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasti M, Khanbabaei H, Teimoori A. An update on enterovirus 71 infection and interferon type I response. Rev. Med. Virol. 2019;29:e2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169063</ArticleId><ArticleId IdType="pubmed">30378208</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, et al. LY294002 and rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway. Mol. Cell Biochem. 2014;385:169–177.</Citation><ArticleIdList><ArticleId IdType="pubmed">24072614</ArticleId></ArticleIdList></Reference><Reference><Citation>Giehl E, et al. In vivo priming of peritoneal tumor-reactive lymphocytes with a potent oncolytic virus for adoptive cell therapy. Front. Immunol. 2021;12:610042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930493</ArticleId><ArticleId IdType="pubmed">33679747</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvin EK, Scarlett CJ. A historical perspective of pancreatic cancer mouse models. Semin. Cell Dev. Biol. 2014;27:96–105.</Citation><ArticleIdList><ArticleId IdType="pubmed">24685616</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M, et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm. Sin. B. 2021;11:2983–2994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546664</ArticleId><ArticleId IdType="pubmed">34729299</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler A, Hazini A, Heimann L, Kurreck J, Fechner H. Coxsackievirus B3-its potential as an oncolytic virus. Viruses. 2021;13:718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8143167</ArticleId><ArticleId IdType="pubmed">33919076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res. Treat. 2014;143:47–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">24292814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, et al. Identification and characterization of a small inhibitory peptide that can target DNA-PKcs autophosphorylation and increase tumor radiosensitivity. Int J. Radiat. Oncol. Biol. Phys. 2012;84:1212–1219.</Citation><ArticleIdList><ArticleId IdType="pubmed">22592045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YH, et al. A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer. Cancer Lett. 2017;400:79–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">28450160</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein C, et al. Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation. Radiat. Oncol. 2017;12:208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747947</ArticleId><ArticleId IdType="pubmed">29287602</ArticleId></ArticleIdList></Reference><Reference><Citation>Riches LC, et al. Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses pre-clinically. Mol. Cancer Ther. 2020;19:13–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">31534013</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X, et al. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nat. Commun. 2018;9:4342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6194050</ArticleId><ArticleId IdType="pubmed">30337542</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, et al. A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5. Emerg. Microbes Infect. 2018;7:185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6246558</ArticleId><ArticleId IdType="pubmed">30459302</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F, et al. An epidemic of coxsackievirus B3 infection in infants and children in Jiangsu Province, China: a prospective cohort study. Arch. Virol. 2016;161:1945–1947.</Citation><ArticleIdList><ArticleId IdType="pubmed">27020571</ArticleId></ArticleIdList></Reference><Reference><Citation>Biacchesi S, et al. Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression. J. Virol. Methods. 2005;128:192–197.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955576</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong R, et al. Long-term infection and pathogenesis in a novel mouse model of human respiratory syncytial virus. Viruses. 2022;14:1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9415064</ArticleId><ArticleId IdType="pubmed">36016362</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeman DS, et al. Lysosome activation clears aggregates and enhances quiescent neural stem cell activation during aging. Science. 2018;359:1277–1283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5915358</ArticleId><ArticleId IdType="pubmed">29590078</ArticleId></ArticleIdList></Reference><Reference><Citation>Junk DJ, et al. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia. 2008;10:450–461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373910</ArticleId><ArticleId IdType="pubmed">18472962</ArticleId></ArticleIdList></Reference><Reference><Citation>Chino H, Hatta T, Natsume T, Mizushima N. Intrinsically disordered protein TEX264 mediates ER-phagy. Mol. Cell. 2019;74:909–921.</Citation><ArticleIdList><ArticleId IdType="pubmed">31006538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, et al. High-throughput screening for TLR3-IFN regulatory factor 3 signaling pathway modulators identifies several antipsychotic drugs as TLR inhibitors. J. Immunol. 2010;184:5768–5776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874113</ArticleId><ArticleId IdType="pubmed">20382888</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentili M, et al. The N-terminal domain of cGAS determines preferential association with centromeric DNA and innate immune activation in the nucleus. Cell Rep. 2019;26:2377–2393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391843</ArticleId><ArticleId IdType="pubmed">30811988</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>